$CRSP earnings report

CASGEVY generated $99 million of third-quarter 2026 revenue, up 30% quarter-over-quarter, while CRISPR Therapeutics reported a $111.4 million net loss and ended the quarter with $2,276.6 million of cash, cash equivalents, and marketable securities. AlphAI read CRISPR Therapeutics's third quarter 2026 filing as mixed. 2 quarters are on record below.

third quarter 2026

AlphAI · Earnings readCRSP · third quarter 2026 · ended September 30, 2026

CASGEVY generated $99 million of third-quarter 2026 revenue, up 30% quarter-over-quarter, while CRISPR Therapeutics reported a $111.4 million net loss and ended the quarter with $2,276.6 million of cash, cash equivalents, and marketable securities.

→Mixed quarter

CASGEVY commercial momentum and pipeline progress were offset by a wider year-over-year net loss, higher research and development expense, acquired in-process R&D expense, and the absence of financial guidance.

Revenue
$12.7M
CASGEVY
$99M
nearly six times the revenue reported in the third quarter of 2025 y/y · 30% q/q

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
CASGEVY revenue, third quarter 2026other$99M30%nearly six times the revenue reported in the third quarter of 2025
Collaboration revenue, three months ended September 30, 2026GAAP$12.32M––
Grant revenue, three months ended September 30, 2026GAAP$346K––
Total revenue, three months ended September 30, 2026GAAP$12.67M––
Research and development expense, three months ended September 30, 2026GAAP$71.89M––
Acquired in-process research and development expense, three months ended September 30, 2026GAAP$11.68M––
General and administrative expense, three months ended September 30, 2026GAAP$17.87M––
Collaboration expense, net, three months ended September 30, 2026GAAP$41.28M––
Total operating expenses, three months ended September 30, 2026GAAP$142.7M––
Loss from operations, three months ended September 30, 2026GAAP−$130.0M––
Total other income, net, three months ended September 30, 2026GAAP$18.68M––
Net loss before income taxes, three months ended September 30, 2026GAAP−$111.4M––
Provision for income taxes, three months ended September 30, 2026GAAP−$74K––
Net loss, three months ended September 30, 2026GAAP−$111.4M––
Foreign currency translation adjustment, three months ended September 30, 2026GAAP$2K––
Unrealized loss on marketable securities, three months ended September 30, 2026GAAP−$9.46M––
Comprehensive loss, three months ended September 30, 2026GAAP−$120.9M––
Net loss per common share, basic, three months ended September 30, 2026GAAP$(1.15)––
Basic weighted-average common shares outstanding, three months ended September 30, 2026GAAP96,741,070––
Net loss per common share, diluted, three months ended September 30, 2026GAAP$(1.15)––
Diluted weighted-average common shares outstanding, three months ended September 30, 2026GAAP96,741,070––
Collaboration revenue, nine months ended September 30, 2026GAAP$23.32M––
Grant revenue, nine months ended September 30, 2026GAAP$985K––
Total revenue, nine months ended September 30, 2026GAAP$24.31M––
Research and development expense, nine months ended September 30, 2026GAAP$207.6M––
Acquired in-process research and development expense, nine months ended September 30, 2026GAAP$14.15M––
General and administrative expense, nine months ended September 30, 2026GAAP$52.60M––
Collaboration expense, net, nine months ended September 30, 2026GAAP$127.5M––
Total operating expenses, nine months ended September 30, 2026GAAP$401.9M––
Loss from operations, nine months ended September 30, 2026GAAP−$377.6M––
Total other income, net, nine months ended September 30, 2026GAAP$53.91M––
Net loss before income taxes, nine months ended September 30, 2026GAAP−$323.6M––
Provision for income taxes, nine months ended September 30, 2026GAAP−$1.87M––
Net loss, nine months ended September 30, 2026GAAP−$325.5M––
Foreign currency translation adjustment, nine months ended September 30, 2026GAAP−$20K––
Unrealized loss on marketable securities, nine months ended September 30, 2026GAAP−$18.88M––
Comprehensive loss, nine months ended September 30, 2026GAAP−$344.4M––
Net loss per common share, basic, nine months ended September 30, 2026GAAP$(3.38)––
Basic weighted-average common shares outstanding, nine months ended September 30, 2026GAAP96,437,995––
Net loss per common share, diluted, nine months ended September 30, 2026GAAP$(3.38)––
Diluted weighted-average common shares outstanding, nine months ended September 30, 2026GAAP96,437,995––
Cash, cash equivalents, and marketable securities, as of September 30, 2026GAAP$2.28B––
Cash and cash equivalents, as of September 30, 2026GAAP$192.0M––
Marketable securities, as of September 30, 2026GAAP$2.08B––
Marketable securities - non-current, as of September 30, 2026GAAP$4.02M––
Working capital, as of September 30, 2026GAAP$2.14B––
Total assets, as of September 30, 2026GAAP$2.56B––
Total shareholders' equity, as of September 30, 2026GAAP$1.65B––

Segments

SegmentRevenueq/qy/y
CASGEVYMore than 750 patients have initiated treatment worldwide, and availability expanded for younger patients through approvals in the U.S., Saudi Arabia, the United Arab Emirates, Bahrain, and the U.K.$99M30%nearly six times the revenue reported in the third quarter of 2025

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

What drove it

  • CASGEVY generated $99 million of third-quarter 2026 revenue, representing 30% growth quarter-over-quarter.
  • Collaboration expense, net, declined to $41.3 million from $57.1 million, primarily attributable to an increase in the Company's share of CASGEVY revenue.
  • Research and development expense increased primarily because of higher external research and development expenses and sublicense fees, partly offset by lower employee-related costs.
  • Acquired in-process R&D expense primarily consisted of a development milestone under the Sirius Agreement recognized in the third quarter of 2026.
  • The FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C.
  • CRISPR Therapeutics completed enrollment in the Phase 2 CTX611 trial in patients undergoing total knee arthroplasty.

Concerns

  • Net loss was $111.4 million for the third quarter of 2026, compared to a net loss of $106.4 million for the third quarter of 2025.
  • Total operating expenses were $142,714 for the third quarter of 2026, compared to $132,948 for the third quarter of 2025.
  • Research and development expense was $71.9 million for the third quarter of 2026, compared to $58.9 million for the third quarter of 2025.
  • The company provided no financial guidance in the filing.
  • The filing states that there is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities.

What to watch

  • Phase 1b CTX310 data in patients with severe hypertriglyceridemia at the American Heart Association Scientific Sessions 2026 on November 9, 2026, at 8:00 a.m. CT.
  • Phase 1 zugo-cel data in patients with refractory systemic sclerosis at ACR Convergence 2026 on November 8 at 10:30 a.m. ET.
  • An update from the Phase 2 CTX611 trial is expected in the second half of 2026.
  • Updates from the Phase 1/2 zugo-cel trial in B-cell malignancies are anticipated in the second half of 2026.
  • Further expansion of CASGEVY access, including uptake among younger pediatric patients following recent approvals.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared to $1,975.8 million as of December 31, 2025.
  • The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses.
  • Working capital was $2,144,117 as of September 30, 2026, compared to $1,836,551 as of December 31, 2025.
  • Total assets were $2,556,412 as of September 30, 2026, compared to $2,265,243 as of December 31, 2025.
  • Total shareholders' equity was $1,648,068 as of September 30, 2026, compared to $1,921,813 as of December 31, 2025.

Analysis

The quarter centered on CASGEVY commercialization. CASGEVY generated $99 million of third-quarter 2026 revenue, up 30% quarter-over-quarter and nearly six times the revenue reported in the third quarter of 2025. The company stated that more than 750 patients have initiated treatment worldwide and that patient availability expanded through approvals for younger children in several markets. The reported collaboration revenue in the consolidated statement of operations was $12,323 for the quarter, compared with $— in the prior-year quarter.

The consolidated income statement remained loss-making. Total revenue was $12,669 for the three months ended September 30, 2026, compared with $889 in the prior-year period, while total operating expenses rose to $142,714 from $132,948. Research and development expense increased to $71,888 from $58,902, and the company recorded $11,675 of acquired in-process research and development expense related primarily to a Sirius Agreement development milestone. Collaboration expense, net, declined to $41,284 from $57,115, which management attributed to an increase in the Company's share of CASGEVY revenue. Net loss was $(111,437), compared with $(106,441).

For the first nine months, total revenue was $24,308 versus $2,646, while total operating expenses were $401,870 versus $512,453. The nine-month net loss was $(325,522), compared with $(450,986). The year-to-date reduction in operating loss reflected substantially lower acquired in-process R&D expense, which was $14,148 compared with $96,253 in the corresponding 2025 period, and lower collaboration expense, net, partly offset by higher R&D expense.

Liquidity increased following financing activity. Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared with $1,975.8 million as of December 31, 2025. The company attributed the increase primarily to net proceeds of $585.4 million from convertible senior notes issued in March 2026, offset by operating expenses. Total shareholders' equity was $1,648,068 as of September 30, 2026, compared with $1,921,813 as of December 31, 2025.

Pipeline execution supplied the other major developments. The FDA granted RMAT designations to CTX310 in severe hypertriglyceridemia and elevated LDL-C, the company completed enrollment in the Phase 2 CTX611 total knee arthroplasty trial, and upcoming disclosures include CTX310 Phase 1b data on November 9, 2026 and zugo-cel systemic sclerosis data on November 8, 2026. The filing did not provide financial guidance, cash runway guidance, capital-return activity, or operating and free cash flow figures.

Management, verbatim

The third quarter marked meaningful progress for CRISPR Therapeutics.

Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics

CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA’s RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease.

Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics

With new clinical data from CTX310 and zugo-cel in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we are entering a pivotal period for our pipeline.

Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics

Not in the filing

stated, not guessed
  • Financial guidance
  • Gross margin
  • Operating cash flow
  • Free cash flow
  • Cash runway guidance
  • Debt balance as of September 30, 2026
  • Share repurchases
  • Dividend information
  • Non-GAAP financial measures
  • Prior-quarter values for consolidated statement of operations metrics
  • Percentage year-over-year changes for consolidated statement of operations metrics
  • The previous outlook covered the second half of 2026 and contained only qualitative clinical update timing, with no reported figures to compare against this quarterly release.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readCRSP · second quarter 2026 · ended June 30, 2026

CRISPR Therapeutics reported second quarter 2026 results with CASGEVY revenue of $76 million, up 78% quarter-over-quarter and 151% year-over-year, while net loss narrowed to $91.2 million.

✓Solid quarter

CASGEVY revenue growth accelerated and operating expense categories declined year-over-year, while the company expanded several clinical programs and ended the quarter with $2,364.4 million of cash, cash equivalents, and marketable securities. The company remained loss-making and reported no financial guidance.

Revenue
$76M
151% growth year-over-year y/y · 78% growth quarter-over-quarter q/q
CASGEVY
$76M
151% growth year-over-year y/y · 78% growth quarter-over-quarter q/q

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
CASGEVY revenueother$76M78% growth quarter-over-quarter151% growth year-over-year
R&D expensesGAAP$67.2M––
Acquired in-process R&D expensesGAAP$2.5M––
General and administrative expensesGAAP$17.6M––
Collaboration expense, netGAAP$40.3M––
Net lossGAAP$91.2M––

Segments

SegmentRevenueq/qy/y
CASGEVYCASGEVY momentum continued to build, including FDA approval for children 2 years of age and older with SCD or TDT.$76M78% growth quarter-over-quarter151% growth year-over-year

second half of 2026 outlook

  • NoteThe Company expects to provide a Phase 1b clinical update for CTX310 in the second half of 2026.
  • NoteThe Company expects to provide an update for CTX611 in the second half of 2026.
  • NoteThe Company expects to provide further updates on the zugo-cel autoimmune clinical program in the second half of 2026.
  • NoteUpdates for the Phase 1/2 clinical trial of zugo-cel in B-cell malignancies are anticipated in the second half of 2026.

What drove it

  • CASGEVY generated second quarter 2026 revenue of $76 million, representing 78% growth quarter-over-quarter and 151% growth year-over-year.
  • The U.S. FDA approved CASGEVY in children 2 years of age and older with SCD or TDT.
  • Vertex secured reimbursement for CASGEVY for eligible patients 12 years and older with SCD or TDT in Germany.
  • CRISPR Therapeutics initiated Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency.
  • The decrease in collaboration expense was primarily attributable to an increase in the Company's share of CASGEVY revenue.

Concerns

  • Net loss was $91.2 million for the second quarter of 2026.
  • Efforts remain underway with government and reimbursement authorities globally to ensure sustainable access for eligible patients.
  • The increase in cash was offset by operating expenses.
  • The company reported no financial revenue, expense, margin, or tax-rate guidance.

What to watch

  • Clinical update of the ongoing Phase 1a trial of CTX310 at the European Society of Cardiology Congress 2026 on August 28 at 4:30 p.m. CET.
  • Phase 1b clinical update for CTX310 expected in the second half of 2026.
  • Update for CTX611 expected in the second half of 2026.
  • Further zugo-cel autoimmune-program updates and B-cell malignancy trial updates anticipated in the second half of 2026.
  • An Lp(a) program update is anticipated in 2026.
  • An update on up to two additional siRNA targets is expected in 2026.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $2,364.4 million as of June 30, 2026, compared to $1,975.8 million as of December 31, 2025.
  • The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses.

Analysis

CASGEVY was the central commercial driver in the second quarter. The therapy generated $76 million of revenue, with 78% growth quarter-over-quarter and 151% growth year-over-year. The FDA approval for children 2 years of age and older with SCD or TDT expands the eligible population, while reimbursement was secured in Germany for eligible patients 12 years and older with SCD or TDT.

The reported expense base declined across R&D, general and administrative expense, and collaboration expense, net, compared with the second quarter of 2025. Acquired in-process R&D expense also declined substantially from the prior-year period, when costs were related to entering the Sirius Agreement. Net loss narrowed to $91.2 million from a net loss of $208.5 million in the second quarter of 2025.

Liquidity increased to $2,364.4 million of cash, cash equivalents, and marketable securities as of June 30, 2026, compared with $1,975.8 million as of December 31, 2025. The company attributed the increase primarily to net proceeds of $585.4 million from convertible senior notes issued in March 2026, offset by operating expenses. No capital-return activity was reported.

Portfolio execution extended beyond CASGEVY. The company initiated Phase 1 trials for CTX340 and CTX460, continued CTX310 development, and advanced CTX611 and zugo-cel across multiple clinical settings. The second-half agenda includes CTX310, CTX611, zugo-cel, and immuno-oncology updates, alongside an anticipated Lp(a) program update. The release did not provide financial revenue, expense, margin, or tax-rate guidance.

Management, verbatim

The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform.

Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics

CASGEVY's momentum continued to build, highlighted by the FDA's approval for children as young as 2 years old, while we expanded our in vivo pipeline with the initiation of Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. We enter the second half of 2026 well positioned, with a number of important milestones ahead across our pipeline.

Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics

Not in the filing

stated, not guessed
  • Total company revenue
  • Total revenue prior-year comparison
  • Total revenue prior-quarter comparison
  • Gross profit
  • Gross margin
  • Operating income or loss
  • Operating expenses total
  • Income tax expense or benefit
  • Tax rate
  • GAAP EPS
  • Non-GAAP EPS
  • Non-GAAP financial metrics
  • Operating cash flow
  • Free cash flow
  • Debt balance as of June 30, 2026
  • Share repurchases
  • Dividends
  • Financial revenue guidance
  • Gross-margin guidance
  • Operating-expense guidance
  • Tax-rate guidance
  • Prior outlook or prior-guidance comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CRSP earnings dates

When is CRISPR Therapeutics's next earnings date?
AlphAI has no date for CRSP yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.